Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer

Show simple item record

dc.contributor.author Fu, Zheng en_US
dc.contributor.author Kitagawa, Yasuhide en_US
dc.contributor.author Shen, Ronglai en_US
dc.contributor.author Shah, Rajal en_US
dc.contributor.author Mehra, Rohit en_US
dc.contributor.author Rhodes, Daniel en_US
dc.contributor.author Keller, Peter J. en_US
dc.contributor.author Mizokami, Atsushi en_US
dc.contributor.author Dunn, Rodney L. en_US
dc.contributor.author Chinnaiyan, Arul M. en_US
dc.contributor.author Yao, Zhi en_US
dc.contributor.author Keller, Evan T. en_US
dc.date.accessioned 2007-03-19T17:26:19Z
dc.date.available 2007-03-19T17:26:19Z
dc.date.issued 2006-02-15 en_US
dc.identifier.citation Fu, Zheng; Kitagawa, Yasuhide; Shen, Ronglai; Shah, Rajal; Mehra, Rohit; Rhodes, Daniel; Keller, Peter J.; Mizokami, Atsushi; Dunn, Rodney; Chinnaiyan, Arul M.; Yao, Zhi; Keller, Evan T. (2006)."Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer." The Prostate 66(3): 248-256. <http://hdl.handle.net/2027.42/49524> en_US
dc.identifier.issn 0270-4137 en_US
dc.identifier.issn 1097-0045 en_US
dc.identifier.uri http://hdl.handle.net/2027.42/49524
dc.identifier.uri http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16175585&dopt=citation en_US
dc.description.abstract BACKGROUND Diminished expression of Raf kinase inhibitor protein (RKIP), an inhibitor of the Raf signaling cascade, promotes prostate cancer (PCa) metastasis in a murine model, suggesting that it is a metastasis suppressor gene. However, the prognostic significance of RKIP expression and its association with metastasis in PCa patients is unknown. METHODS To investigate RKIP protein expression is a prognostic marker in PCa we performed immunohistochemical staining for RKIP expression in tissue microarrays consisting of 758 non-neoplastic prostate tissues, primary tumors and metastases from 134 PCa patients. The Cox proportional-hazards model was used to adjust for covariates including Gleason score, tumor volume, tumor weight, clinical stage, digital rectal exam findings, serum PSA level and surgical margins. RESULTS RKIP expression was low in approximately 5%, 48%, and 89%of non-neoplastic prostate, primary tumors and metastases, respectively. Low RKIP expression in primary tumors was a strong positive predictive factor for PCa recurrence based on PSA levels. In patients whose primary tumors expressed high RKIP levels, the 7-year PSA recurrence rate was < 10%; whereas in patients with tumors with low RKIP expression the recurrence rate was 50% ( P  < 0.001). Multivariate analysis revealed RKIP was an independent prognostic factor ( P  < 0.001). CONCLUSION In contrast to increased expression of pro-tumorigenic genes, these results demonstrate decreased protein expression of a gene, for example, RKIP, can serve as a prognostic marker in PCa patients. © 2005 Wiley-Liss, Inc. en_US
dc.format.extent 215122 bytes
dc.format.extent 3118 bytes
dc.format.mimetype application/pdf
dc.format.mimetype text/plain
dc.publisher Wiley Subscription Services, Inc., A Wiley Company en_US
dc.subject.other Life and Medical Sciences en_US
dc.subject.other Cancer Research, Oncology and Pathology en_US
dc.title Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer en_US
dc.type Article en_US
dc.rights.robots IndexNoFollow en_US
dc.subject.hlbsecondlevel Internal Medicine and Specialties en_US
dc.subject.hlbtoplevel Health Sciences en_US
dc.description.peerreviewed Peer Reviewed en_US
dc.contributor.affiliationum Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan en_US
dc.contributor.affiliationum Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan en_US
dc.contributor.affiliationum Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan en_US
dc.contributor.affiliationum Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan en_US
dc.contributor.affiliationum Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan en_US
dc.contributor.affiliationum Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan en_US
dc.contributor.affiliationum Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan en_US
dc.contributor.affiliationum Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan en_US
dc.contributor.affiliationum Departments of Urology and Pathology, University of Michigan, Ann Arbor, Michigan ; Room 5304, CCGC building, 500 E. Medical Center Dr., University of Michigan, Ann Arbor, MI 48109-0940. en_US
dc.contributor.affiliationother Department of Urology, Kanazawa University, Kanazawa City, Japan en_US
dc.contributor.affiliationother Department of Urology, Kanazawa University, Kanazawa City, Japan en_US
dc.contributor.affiliationother Department of Immunology, Tianjin Medical University, Tianjin, China en_US
dc.identifier.pmid 16175585 en_US
dc.description.bitstreamurl http://deepblue.lib.umich.edu/bitstream/2027.42/49524/1/20319_ftp.pdf en_US
dc.identifier.doi http://dx.doi.org/10.1002/pros.20319 en_US
dc.identifier.source The Prostate en_US
dc.owningcollname Interdisciplinary and Peer-Reviewed
 Show simple item record

This item appears in the following Collection(s)


Search Deep Blue

Advanced Search

Browse by

My Account

Information

Available Now


MLibrary logo